المؤلفون: O. V. Svetlova, I. V. Gurieva, D. V. Kuzina, A. V. Voronin, О. В. Светлова, И. В. Гурьева, И. В. Кузина, А. В. Воронин

المصدر: Meditsinskiy sovet = Medical Council; № 23 (2023); 192-200 ; Медицинский Совет; № 23 (2023); 192-200 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: инсулинорезистентность, therapeutic goals, metformin, glycemic control, insulin resistance, терапевтические цели, метформин, контроль гликемии

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8018/7110; Дедов ИИ, Шестакова МВ, Майоров АЮ. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. М.; 2023. 234 с. Режим доступа: https://webmed.irkutsk.ru/doc/pdf/algosd.pdf.; Дедов ИИ, Шестакова МВ, Галстян ГР. Распространенность сахарного диабета 2-го типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104–112. https://doi.org/10.14341/DM2004116-17.; Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412. https://doi.org/10.1136/bmj.321.7258.405.; Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865. Available at: https://pubmed.ncbi.nlm.nih.gov/9742977.; Бирюкова ЕВ, Шинкин МВ, Соловьева ИВ. Современная практика самоконтроля гликемии: основы эффективного управления сахарным диабетом. Клинический разбор в общей медицине. 2023;4(2):60–67 https://doi.org/10.47407/kr2023.4.2.00205.; Светлова ОВ, Гурьева ИВ. Инновационные технологии в управлении сахарным диабетом: предупреждение гипогликемии. Медицинский совет. 2023;17(9):89–95. https://doi.org/10.21518/ms2023-167.; Светлова ОВ, Гурьева ИВ, Савченко ЛС. Современные возможности самоконтроля: Новая эра эффективного управления сахарным диабетом. Медицинский совет. 2019;(4):30–33. https://doi.org/10.21518/2079701X-2019-4-30-33.; Моргунова ТБ, Глинкина ИВ, Пешева ЕД, Зорина АА, Фадеев ВВ. Место метформина в современных клинических рекомендациях по лечению сахарного диабета 2-го типа. Медицинский совет. 2023;17(13):122–129. https://doi.org/10.21518/ms2023-211.; Моргунов ЛЮ. Сиофор: плейотропные эффекты в реальной клинической практике. Эффективная фармакотерапия. Эндокринология. 2014;(5):46. Режим доступа: https://umedp.ru/articles/siofor_pleyotropnye_effekty_v_realnoy_klinicheskoy_praktike.html?forgot_password=yes&%2Farticles%2Fsiofor_pleyotropnye_effekty_v_realnoy_klinicheskoy_praktike_html.; Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–1593. https://doi.org/10.1007/s00125-017-336-x.; Introduction: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(1):1–2. https://doi.org/10.2337/dc18-Sint01.; Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017;19(4):473–481. https://doi.org/10.1111/dom.12854.; Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care. 1989;12(8):553–564. https://doi.org/10.2337/diacare.12.8.553.; Sivitz WI, Phillips LS, Wexler DJ, Fortmann SP, Camp AW, Tiktin M. et al. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care. 2020;43(5):940–947. https://doi.org/10.2337/dc19-1769.; Walker EA, Gonzalez JS, Tripputi MT, Dagogo-Jack S, Matulik MJ, Montez MG et al. Group. Long-term metformin adherence in the Diabetes Prevention Program Outcomes Study. BMJ Open Diabetes Res Care. 2020;8(1):e001537. https://doi.org/10.1136/bmjdrc-2020-001537.; Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2020. Endocr Pract. 2020;26(1):107–139. https://doi.org/10.4158/CS-2019-0472.; Patel-Sanchez N, Perito E, Tsai P, Raymond-Flesch M, Lodish M, Sarkar M. Prevalence of nonalcoholic fatty liver disease increased with type 2 diabetes mellitus in overweight/obese youth with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2023;36(5):441–446. https://doi.org/10.1515/jpem-2022-0527.; Stedman M, Rea R, Duff CJ, Livingston M, McLoughlin K, Wong L et al. People with Type Diabetes Mellitus (T1DM) self-reported views on their own condition management reveal links to potentially improved outcomes and potential areas for service improvement. Diabetes Res Clin Pract. 2020;170:108479. https://doi.org/10.1016/j.diabres.2020.108479.; Дедов ИИ, Шестакова МВ, Викулова ОК, Железнякова АВ, Исаков МА. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204–221. https://doi.org/10.14341/DM12759.; Kautzky-Willer A, Michael Leutner M, Jürgen Harreiter J. Sex differences in type 2 diabetes. Diabetologia. 2023;66(6):986–1002. https://doi.org/10.1007/s00125-023-05891-x.; Hong SH, Sung YA, Hong YS, Song DK, Jung H, Jeong K et al. Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome. Sci Rep. 2023;13(1):13397. https://doi.org/10.1038/s41598-023-39428-4.; Abu-Freha N, Cohen B, Weissmann S, Hizkiya R, Abu-Hammad R, Gadeer Taha G, Gordon M. Comorbidities and Outcomes among Females with Non-Alcoholic Fatty Liver Disease Compared to Males. Biomedicines. 2022;10(11):2908. https://doi.org/10.3390/biomedicines10112908.; Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13:123. https://doi.org/10.1186/s12933-014-0123-x.; DiStefano JK. The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women. Nutrients. 2023;15(12):2670. https://doi.org/10.3390/nu15122670.; Соколова АВ, Климова АВ, Драгунов ДО, Арутюнов ГП. Оценка влияния терапии метформином на величину мышечной массы и мышечной силы у больных с и без сахарного диабета. Метаанализ 15 исследований. Российский кардиологический журнал. 2021;26(3):4331. https://doi.org/10.15829/1560-4071-2021-4331.; Григорьева ИИ, Раскина ТА, Летаева МВ, Малышенко ОС, Аверкиева ЮВ, Масенко ВЛ, Коков АН. Саркопения: особенности патогенеза и диагностики. Фундаментальная и клиническая медицина. 2019;4(4):105–116. https://doi.org/10.23946/2500-0764-2019-4-4-105-116.; Rodriguez Moctezuma JR, Robles López G, López Carmona JM, Gutiérrez- Rosas MJ. Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes Obes Metab. 2005;7(2):189–192. https://doi.org/10.1111/j.1463-1326.2004.00385.x.; Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21(3):300–307. https://doi.org/10.1016/j.jamda.2019.12.012.; Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–1529. https://doi.org/10.1016/s0140-6736(19)32131-2.; Wee AKH, Sultana R. Determinants of vitamin B12 deficiency in patients with type-2 diabetes mellitus – A primary-care retrospective cohort study. BMC Prim Care. 2023;24(1):102. https://doi.org/10.1186/s12875-023-02057-x.; Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29(4):759–764. https://doi.org/10.2337/diacare.29.04.06.dc05-1967.; Rathis TS, Ranganathan RS, Solai Raja M, Srivastav PSS. Prevalence of Vitamin B12 Deficiency in Type 2 Diabetes Mellitus Patients on Metformin Therapy. Cureus. 2023;15(4):e37466. https://doi.org/10.7759/Cureus.37466.; Kim J, Ahn CW, Fang S, Lee HS, Park JS. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine (Baltimore). 2019;98(46):e17918. https://doi.org/10.1097MD.0000000000017918.; https://www.med-sovet.pro/jour/article/view/8018

الاتاحة: https://www.med-sovet.pro/jour/article/view/8018
https://doi.org/10.21518/ms2023-466

المؤلفون: L. Morgunov Yu., Л. Моргунов Ю.

المصدر: Research and Practical Medicine Journal; Том 4, № 4 (2017); 110-124 ; Исследования и практика в медицине; Том 4, № 4 (2017); 110-124 ; 2410-1893 ; 2409-2231 ; 10.17709/2409-2231-2017-4-4

مصطلحات موضوعية: diabetes mellitus, treatment, elderly, hypoglycemia, therapeutic goals, incretins, сахарный диабет, лечение, пожилые, гипогликемия, терапевтические цели, инкретины

وصف الملف: application/pdf

Relation: https://www.rpmj.ru/rpmj/article/view/226/213; Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова. 8-й выпуск. М., 2017, 112 с./Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol’nym sakharnym diabetom [Algorithms of specialized medical care for patients with diabetes mellitus]. Ed by I. I. Dedov. 8th ed. Мosocw, 2017, 112 p. (In Russian).; Gómez Huelgas R, Díez-Espino J, Formiga F, Lafita Tejedor J, Rodríguez Mañas L, González-Sarmiento E, Menéndez E, Sangrós J. Treatment of type 2 diabetes in the elderly. Med Clin (Barc). 2013 Feb 2;140 (3): 134.e1–134.e12. DOI:10.1016/j.medcli.2012.10.003; Pratley RE, Heller SR, Miller MA. Treatment of type 2 diabetes mellitus in the older adult: a review. Endocr Pract. 2014 Jul;20 (7):722–36. DOI:10.4158/EP13192.RA; Abbatecola AM, Paolisso G, Sinclair AJ. Treating diabetes mellitus in older and oldest old patients. Curr Pharm Des. 2015; 21 (13): 1665–71. DOI:10.2174/1381612821666150130120747; Budyono C, Setiati S, Purnamasari D, Rumende CM. The Proportion of Orthostatic Hypotension and Its Relationship with HbA1c Levels in Elderly Patients with Diabetes. Acta Med Indones. 2016 Apr; 48 (2): 122–8. http://www.inaactamedica.org/archives/2016/27550881.pdf; Mitrakou A, Katsiki N, Lalic NM. Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia. Curr Vasc Pharmacol. 2017; 15 (1): 19–29. DOI:10.2174/1570161114666160822154816; Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011 May;34 (5):1164–70. DOI:10.2337/dc10–1915.; Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009 Apr 15;301 (15):1565–72. DOI:10.1001/jama.2009.460; Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging. 2008;25 (11):913–25. DOI:10.2165/0002512–200825110–00002; Hanefeld M, Ganz X, Nolte C. Hypoglycemia and cardi ac arrhythmia in patients with diabetes mellitus type 2. Herz. 2014 May;39 (3):312–9. doi:10.1007/s00059–014–4086–1; Sircar M, Bhatia A, Munshi M. Review of Hypoglycemia in the Older Adult: Clinical Implications and Management. Can J Diabetes. 2016 Feb; 40 (1): 66–72. DOI:10.1016/j.jcjd.2015.10.004; Nguyen HT, Arcury TA, Grzywacz JG, Saldana SJ, Ip EH, Kirk JK, et al. The association of mental conditions with blood glucose levels in older adults with diabetes. Aging Ment Health. 2012;16 (8):950–7. DOI:10.1080/13607863.2012.688193; Nandipati S, Luo X, Schimming C, Grossman HT, Sano M. Cognition in non-demented diabetic older adults. Curr Aging Sci. 2012; 5 (2): 131–5. DOI:10.2174/1874609811205020131; Boels AM, Hart HE, Rutten GE, Vos RC. Personalised treatment targets in type 2 diabetes patients: The Dutch approach. Prim Care Diabetes. 2017 Feb; 11 (1): 71–7. DOI:10.1016/j.pcd.2016.08.00; Pratley RE, Gilbert M. Clinical management of elderly patients with type 2 diabetes mellitus. Postgrad Med. 2012 Jan;124 (1):133–43. DOI:10.3810/pgm.2012.01.2526; American Diabetes Association Standards of medical care in diabetes — 2012. Diabetes Care. 2012;35 (Suppl 1): S11-S63.; American Diabetes Association Standards of medical care in diabetes — 2013. Diabetes Care. 2013; 36 (Suppl 1): S11–S66. DOI:10.2337/dc13-S011; Lee SJ, Boscardin WJ, Stijacic CI, Huang ES, Rice-Trumble K, Eng C. The risks and benefits of implementing glycemic control guidelines in frail older adults with diabetes mellitus. J Am Geriatr Soc. 2011 Apr;59 (4):666–72. DOI:10.1111/j.1532–5415.2011.03362.x.; VA/DoD clinical practice guideline for the management of diabetes mellitus. Version 4.0. Washington, DC: Veterans Health Administration and Department of Defense; 2010.; Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011 Apr 19;154 (8):554–9. DOI:10.7326/0003–4819–154–8-201104190–00007.; Sinclair A, Morley JE, Rodriguez-Manas L, Paolisso G, Bayer T, Zeyfang A, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012 Jul;13 (6):497–502. DOI:10.1016/j.jamda.2012.04.012.; Major K, Saiah L, Rubli E, Rochat S, Monod S, Büla C. Review in geriatric medicine 2012. Rev Med Suisse. 2013 Jan 9; 9 (368): 40–3.; Deletre S, Coutaz M. Diabetes: glycemic targets and over-treatment in older patients. Rev Med Suisse. 2016 Mar 2;12 (508):461–4, 466; Thompson AM, Linnebur SA, Vande Griend JP, Saseen JJ. Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult. Consult Pharm. 2014 Feb; 29 (2): 110–23. DOI:10.4140/TCP.n.2014.110; Zeyfang A. Individualized diabetes therapy in older persons]. Internist (Berl). 2016 May; 57 (5): 502–7. DOI:10.1007/s00108–016–0039–5; Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschöpe D. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol. 2012 Oct 6;11:122. DOI:10.1186/1475–2840–11–122; Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008 Nov;31 (11):2086–91. DOI:10.2337/dc08–1171; Formiga F, Gómez-Huelgas R, Rodríguez Mañas L. Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors. Rev Esp Geriatr Gerontol. 2016 JanFeb;51 (1):44–51. DOI:10.1016/j.regg.2015.04.002; Freeman J. Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies. J Fam Pract. 2015 Dec;64 (12 Suppl): S59–66; Abbatecola AM, Paolisso G. Diabetes care targets in older persons. Diabetes Res Clin Pract. 2009 Dec;86 Suppl 1: S35–40. DOI:10.1016/S0168–8227(09)70007–5; Germino FW. Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review. Clin Ther. 2011 Dec; 33 (12): 1868–82. DOI:10.1016/j.clinthera.2011.10.020; Fu H, Curtis BH, Schuster DP, Festa A, Kendall DM. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study. Diabetes Technol Ther. 2014 Dec; 16 (12): 833–9. DOI:10.1089/dia.2014.0039; Clinicaltrials.gov. Study of Sitagliptin in Older Type 2 Diabetics (Clincal trial identifier NCT00305604), 2013; Fernández MA. Treatment of older persons with diabetes. Semergen. 2014 May;40 Suppl 1:10–6. DOI:10.1016/S1138–3593(14)74382–5; Russell S. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Int J Clin Pharm. 2013 Apr;35 (2):159–72. DOI:10.1007/s11096–012–9729–9; Bourdel-Marchasson I, Schweizer A, Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hosp Pract (1995). 2011 Feb;39 (1):7–21. DOI:10.3810/hp.2011.02.369; Halimi S, Raccah D, Schweizer A, Dejager S. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin. 2010 Jul;26 (7):1647–56. DOI:10.1185/03007995.2010.485881; Tasci I, Naharci MI, Bozoglu E, Safer U, Aydogdu A, Yilmaz BF, et al. Cognitive and functional influences of vildagliptin, A DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. Endocr Metab Immune Disord Drug Targets. 2013 Sep;13 (3):256–63. DOI:10.2174/18715303113139990037; Barnett A, Huisman H, Jones R, et al. Efficacy and safety of Linagliptin in elderly patients (>/=70 Years) with type 2 diabetes [abstract 1017-P]. Diabetes. 2012;61: A260–A261.; Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011 May;27 (5):1049–58. DOI:10.1185/03007995.2011.568059; Shankar R, Engel S, Xu L, et al. Sitagliptin provides similar glycemic improvement with less hypoglycemia in the elderly with type 2 diabetes mellitus compared to sulfonylurea. Diabetes. 2012;61: A278.; St Onge EL, Miller S, Clements E. Sitagliptin/metformin (Janumet) as combination therapy in the treatment of type-2 diabetes mellitus. Pharm Ther. 2012; 37 (12): 699–708.; Charbonnel B, Barnett A, Monyak J, et al. Efficacy and safety of saxagliptin in combination with insulin in elderly patients with type 2 diabetes [abstract 1048-P]. Diabetes. 2012; 61: A269.; Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298 (2):194–206. DOI:10.1001/jama.298.2.194; Pratley RE. Linagliptin use in older individuals with type 2 diabetes. Clin Interv Aging. 2014 Jul 16;9:1109–14. doi:10.2147/CIA.S62877; Triplitt CL. Managing diabetes in patients with diabetes of long duration. Diabetes Educ. 2012 Jul-Aug;38 (4 Suppl):23S-30S; quiz 31S. DOI:10.1177/0145721712449390; Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012 Jul;124 (4):21–32. DOI:10.3810/pgm.2012.07.2567; Bode BW, Brett J, Falahati A, Pratley RE. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes >/=65 and; Raccah D, Miossec P, Esposito V, Niemoeller E, Cho M, Gerich J. Efficacy and safety of lixisenatide in elderly (>65 yr) and very elderly (>/=75 yr) patients with type 2 diabetes: an analysis from the GetGoal Phase 3 Program. Diabetes Metab Res Rev. 2015 Feb;31 (2):204–11. DOI:10.1002/dmrr.2588; Rajagopalan R, Xu Y, Abbadessa M; Quartet Study Group. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials. Am J Geriatr Pharmacother. 2006 Jun;4 (2):123–33. DOI:10.1016/j.amjopharm.2006.06.003; GLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012; 8:495–502. DOI:10.1038/nrendo.2011.243.; Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013 Apr;41 (2):72–84. DOI:10.3810/hp.2013.04.1020; Graillot D, Quipourt V, Bouillet B, Petit JM, Manckoundia P. Type 2 diabetes in the elderly, which specific features?. Rev Med Interne. 2012 Oct; 33 (10): 575–9. DOI:10.1016/j.revmed.2012.06.001; Tanwani LK. Insulin therapy in the elderly patient with diabetes. Am J Geriatr Pharmacother. 2011 Feb;9 (1):24–36. DOI:10.1016/j.amjopharm.2011.02.006; Zafon C, Creus C. A comparison on insulin regimen treatment of elderly (>70 years) and younger (; Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009 Sep-Oct; 15 (6): 540–59. DOI:10.4158/EP.15.6.540; Lee P, Chang A, Blaum C, Vlajnic A, Gao L, Halter J. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis. J Am Geriatr Soc. 2012 Jan;60 (1):51–9. DOI:10.1111/j.1532–5415.2011.03773.x; Garber AJ, Clauson P, Pedersen CB, Kølendorf K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc. 2007 Nov;55 (11):1735–40. DOI:10.1111/j.1532–5415.2007.01414.x; Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012 Aug;29 (8):2104–14. doi:10.1007/s11095–012–0739-z; Ratner RE, Gough SCL, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a preplanned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013 Feb;15 (2):175–84. DOI:10.1111/dom.12032.; Gough S, Ratner R, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Prospectively planned meta-analysis comparing hypoglycaemia rates of insulin degludec with those of insulin glargine in all patients and an elderly (>65 year) subgroup [poster]. European Association for the Study of Diabetes: October 1, 2012; Berlin, Germany.; Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rod bard HW, Johansen T, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012 Dec;35 (12):2464–71. DOI:10.2337/dc12–1205; Abbatecola AM, Paolisso G, Corsonello A, Bustacchini S, Lattanzio F. Antidiabetic oral treatment in older people: does frailty matter? Drugs Aging. 2009 Dec;26 Suppl 1:53–62. DOI:10.2165/11534660–000000000–00000.; Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009 Dec; 7 (6): 324–42. DOI:10.1016/j.amjopharm.2009.12.002; Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. Drugs Aging. 2008; 25 (7): 611–22.; https://www.rpmj.ru/rpmj/article/view/226

الاتاحة: https://www.rpmj.ru/rpmj/article/view/226
https://doi.org/10.17709/2409-2231-2017-4-4-12

المؤلفون: Бывальцев В.А.1

مصطلحات موضوعية: molecular pathogenesis, генетические полиморфизмы, genetic polymorphisms, церебральные артерио-венозные мальформации, цитокины, inflammation, потенциальные терапевтические цели, cerebral arteriovenous malformations, General Medicine, воспаление, cytokines, potential therapeutic targets, молекулярный патогенез

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::cde4dfbb51222adb95e831ebf7286ea1

المؤلفون: Verkhovskaya, Irina, Petrov, Evgeny, Verkhovskiy, Alexander

المصدر: MATEC Web of conferences. 2016. Vol. 79. P. 01058 (1-5)

مصطلحات موضوعية: ксенон, питьевая вода, профилактические цели, терапевтические цели

وصف الملف: application/pdf

Relation: vtls:000622701; http://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000622701

الاتاحة: https://doi.org/10.1051/matecconf/20167901058
http://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000622701